(8CI,9CI)-1,2,3,3a,4,5-六氢吡咯并[1,2-a]喹噁啉 | 92622-53-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (8CI,9CI)-1,2,3,3a,4,5-六氢吡咯并[1,2-a]喹噁啉
• 英文名称: 1,2,3,3a,4,5-hexahydropyrrolo<1,2-a>quinoxaline
• 英文别名: 1,2,3,3a,4,5-hexahydro-pyrrolo[1,2-a]quinoxaline；1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinoxaline；1,2,3,3a,4,5-Hexahydro-pyrrolo<1,2-a>chinoxalin
• CAS: 92622-53-2；18019-17-5
• 化学式: C₁₁H₁₄N₂
• 分子量: 174.246
• InChiKey: IZAIOGMVPVWOKY-UHFFFAOYSA-N

物化性质

• 熔点：
  97-98 °C(Solv: water (7732-18-5); ethanol (64-17-5))
• 沸点：
  315.5±22.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)
• 溶解度：
  12.7 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (8CI,9CI)-1,2,3,3a,4,5-六氢吡咯并[1,2-a]喹噁啉 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 丙酮 为溶剂， 反应 21.0h， 生成 1,2,3,3a,4,5-hexahydro-5-[(2,6-dimethoxyphenyl)methyl]pyrrolo[1,2-a]quinoxaline
  参考文献：
  名称：

  Tetrahydropyrrolo[1,2-a]quinoxalines and tetrahydropyrrolo[1,2-a]pyrido[3,2-a]pyrazines: vascular smooth muscle relaxants and antihypertensive agents

  摘要：

  A series of tetrahydropyrrolo[1,2-a]quinoxalines and tetrahydropyrrolo[1,2-a]pyrido[3,2-a]pyrazines were synthesized and tested for their ability to relax K+-depolarized aortic smooth muscle and antihypertensive activity. It was shown that compounds producing the most relaxation of aortic smooth muscle (5-[2,6-dimethoxyphenyl)methyl]-1,2,3,3a-tetrahydropyrrolo[1,2-a] quinoxalin-4(5H)-one and 5-[(2,6-dimethoxyphenyl)methyl]-5,6,6a,7,8,9-hexahydropyrrolo[1,2- a] pyrazine, 10 and 19, respectively) demonstrated the least hypotensive activity. Those compounds that were the most effective hypotensive agents (6a,7,8,9-tetrahydro-5-(phenylmethyl)pyrido[3,2-a]pyrrolo[1,2-a]++ +pyrazin- 6(5H)-one and 6a,7,8,9-tetrahydro-5-(4-pyridinylmethyl)pyrido[3,2-e]pyrrolo [1,2-a]pyrazin-6(5H)-one, 12 and 13, respectively) displayed little vascular smooth muscle relaxant activity.

  DOI：

  10.1021/jm00378a039
• 作为产物：
  描述：

  -1,2,3四氢吡咯并[1,2-A]喹喔-4(5H)-酮 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 18.0h， 以80%的产率得到(8CI,9CI)-1,2,3,3a,4,5-六氢吡咯并[1,2-a]喹噁啉
  参考文献：
  名称：

  Tetrahydropyrrolo[1,2-a]quinoxalines and tetrahydropyrrolo[1,2-a]pyrido[3,2-a]pyrazines: vascular smooth muscle relaxants and antihypertensive agents

  摘要：

  A series of tetrahydropyrrolo[1,2-a]quinoxalines and tetrahydropyrrolo[1,2-a]pyrido[3,2-a]pyrazines were synthesized and tested for their ability to relax K+-depolarized aortic smooth muscle and antihypertensive activity. It was shown that compounds producing the most relaxation of aortic smooth muscle (5-[2,6-dimethoxyphenyl)methyl]-1,2,3,3a-tetrahydropyrrolo[1,2-a] quinoxalin-4(5H)-one and 5-[(2,6-dimethoxyphenyl)methyl]-5,6,6a,7,8,9-hexahydropyrrolo[1,2- a] pyrazine, 10 and 19, respectively) demonstrated the least hypotensive activity. Those compounds that were the most effective hypotensive agents (6a,7,8,9-tetrahydro-5-(phenylmethyl)pyrido[3,2-a]pyrrolo[1,2-a]++ +pyrazin- 6(5H)-one and 6a,7,8,9-tetrahydro-5-(4-pyridinylmethyl)pyrido[3,2-e]pyrrolo [1,2-a]pyrazin-6(5H)-one, 12 and 13, respectively) displayed little vascular smooth muscle relaxant activity.

  DOI：

  10.1021/jm00378a039

文献信息

• [EN] SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF BROMODOMAIN<br/>[FR] PYRROLOPYRIDINES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE BROMODOMAINES
  申请人：GENENTECH INC

  公开号：WO2016077380A1

  公开（公告）日：2016-05-19

  The present invention relates to compounds of formula (I) and to salts thereof, wherein R1, R2, and Q have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.

  本发明涉及公式(I)的化合物及其盐，其中R1、R2和Q具有规范中定义的任何值，以及其组合物和用途。这些化合物可用作溴结域的抑制剂。还包括包含公式(I)的化合物或其药学上可接受的盐的药物组合物，以及在治疗各种溴结域介导的疾病中使用这些化合物和盐的方法。
• Tetra- and hexa-hydropyrrolo(1,2-a)quinoxaline and azaquinoxaline
  申请人：American Home Products Corporation

  公开号：US04446323A1

  公开（公告）日：1984-05-01

  Tetra- and hexa-hydropyrrolo[1,2-a]quinoxaline and azaquinoxaline derivatives of the formula: ##STR1## in which X is O or H.sub.2 ; Y is CH or N; R is hydrogen, alkyl, dialkylaminoalkyl, arylalkyl, phenoxyalkyl, benzoyl, pyridylalkyl or variations thereof; and R.sup.1 is hydrogen, alkyl, alkoxy, nitro, halo, trifluoromethyl, amino, alkylamino or dialkylamino; or pharmaceutically acceptable salts thereof; are anti-hypertensive agents.

  公式为：##STR1## 其中，X为O或H.sub.2；Y为CH或N；R为氢、烷基、二烷基氨基烷基、芳基烷基、苯氧基烷基、苯甲酰基、吡啶基烷基或其变化物；R.sup.1为氢、烷基、烷氧基、硝基、卤素、三氟甲基、氨基、烷基氨基或二烷基氨基；或其药学上可接受的盐；可用作降压剂。
• TRICYCLIC QUINOLINE AND QUINOXALINE DERIVATIVES
  申请人：AbbVie Inc.

  公开号：US20140080816A1

  公开（公告）日：2014-03-20

  The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT 2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT 2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT 2C receptor.

  本发明涉及三环喹啉和喹噁啉衍生物，以及含有这些化合物的药物组合物，它们的用途为5-HT2C受体的调节剂，特别是激动剂或部分激动剂，用于制备用于预防或治疗对5-HT2C受体调节有反应的病症和疾病的药物，以及用于预防或治疗对5-HT2C受体调节有反应的病症和疾病的方法。
• Tricyclic quinoline and quinoxaline derivatives
  申请人：AbbVie Deutschland GmbH & Co. KG

  公开号：US10118926B2

  公开（公告）日：2018-11-06

  The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.

  本发明涉及三环喹啉和喹喔啉衍生物，涉及含有此类化合物的药物组合物，涉及它们作为 5-HT2C 受体调节剂（尤其是激动剂或部分激动剂）的用途，涉及它们用于制备预防或治疗对 5-HT2C 受体调节有反应的病症和紊乱的药物，还涉及一种预防或治疗对 5-HT2C 受体调节有反应的病症和紊乱的方法。
• ABOU-GHARBIA, MAGID;FREED, M. E.;MCCAULLY, R. J.;SILVER, P. J.;WENDT, R. +, J. MED. CHEM., 1984, 27, N 12, 1743-1746
  作者：ABOU-GHARBIA, MAGID、FREED, M. E.、MCCAULLY, R. J.、SILVER, P. J.、WENDT, R. +

  DOI：——

  日期：——